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Vandetanib is a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, rearranged 
during transfection (RET), and epidermal growth factor receptor, all of which are in involved in the 
pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib in patients with 
advanced pancreatic cancer. 
Methods 
Treatment-naïve adult patients with locally advanced or metastatic pancreatic ductal adenocarcinoma with 
an ECOG performance status of 0–2 were recruited into a phase II double-blind multicentre randomised 
placebo-controlled trial. Patients were randomly assigned (1:1) to receive 300mg/day vandetanib once 
daily or placebo.  In addition all patients were to have gemcitabine (1000mg/m
2  
30min intravenous 
infusion, weekly for seven weeks followed by a one week break then a cycle of weekly treatment for three 
weeks with a one-week break), until disease progression. The primary outcome measure was overall 
survival.  
Findings 
142 patients were randomised and analysis was undertaken with 131 deaths after a median follow up of 
24·9 months. The median (95% confidence interval [CI]) overall survival in the 70 patients randomised to 
gemcitabine and placebo was 8·95 (6·55-11·7) months and 8·83 (7·11-11·6) months in the 72 patients 
randomised to gemcitabine and vandetanib (hazard ratio = 1·21, 95% CI = 0·85, 1·73; log rank X21df = 1·1; P 
= 0·303).  Compared to the control arm the median (95% CI) survival in patients randomised to 
gemcitabine and vandetanib was 11·92 (10·89 – NA) months for the 14 patients developing a grade >2 
rash, and 7·76 (4·34 – 1·15) months for the 58 patients who did (log rank Χ2 2df = 7·23; P= 0·027).  
Interpretation 
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The addition of vandetanib to gemcitabine did not improve overall survival in advanced pancreatic cancer.  
Funding 
Cancer Research UK and Astra Zeneca 
INTRODUCTION 
With poor survival and around 338,000 new cases diagnosed worldwide, pancreatic cancer seems set to 
become the second leading cause of cancer mortality; unless new therapies for advanced pancreatic 
cancer can be developed (1). The survival improvement from systemic chemotherapies has been small 
relative to the advances seen in other adenocarcinomas. A regimen comprising folinic acid, 5-fluorouracil, 
irinotecan and oxaliplatin (FOLFIRINOX) produces the largest increase in median overall survival for 
patients with metastatic disease, from 6·8 months with gemcitabine to 11·1 months with FOLFIRINOX and 
a corresponding increase in one year survival from 20·6% to 48·4%, respectively (2). This regimen is 
associated with significant toxicity and many patients are not sufficiently fit to tolerate it and gemcitabine 
monotherapy remains a standard option for such patients. The median overall survival for patients with 
metastatic disease treated with gemcitabine and nab-paclitaxel was 8·5 months compared to 6·7 months 
for gemcitabine monotherapy, with 35% of patients alive at one year with the combination compared to 
22% for gemcitabine alone (3).  
The combination of the epidermal growth factor receptor (EGFR) inhibitor erlotinib with gemcitabine 
showed a marginally-improved median survival in patients with locally advanced and metastatic disease of 
6·2 months compared to 5·9 months with gemcitabine alone (4). Patients treated with erlotinib and 
experiencing ≥ grade 2 rash, which is a presumed marker of more effective EGFR inhibition had a better 
median overall survival of 10·5 months (4). The addition of the vascular endothelial growth factor (VEGF) 
inhibitor bevacizumab to the gemcitabine-erlotinib backbone also improved progression free survival but 
not overall survival (5).  
ViP/Lancet Oncology/Revised Tracked   3rd November 2016 
Page 5 of 35 
 
Vandetanib is a multi-targeted tyrosine kinase inhibitor of the epithelial growth factor receptor (EGFR), 
vascular epithelial growth factor (VEGF) receptor-2 (VEGFR-2) and the receptor encoded by the proto-
oncogene called REarranged during Transfection (RET). Vandetanib is a once-daily oral agent and the only 
RET inhibitor currently available that selectively targets RET, VEGFR, and EGFR signalling (6, 7). RET is the 
receptor for the glial-derived neurotrophic factor (GDNF) family ligands (GDFLs). Vandetanib inhibits RET 
auto-phosphorylation, RET-dependent extracellular signal-regulated kinase (ERK) phosphorylation and 
tumour pathogenesis (7). It inhibits oncogenic RET isoforms and wild type RET tyrosine kinase with equal 
potency. Neural invasion through GDNF secretion is a prominent feature of pancreatic cancer (8). Neuro-
invasive pancreatic cancer cells in contact with nerves become elongated and migrate along the nerves; 
attracted along a GDNF gradient (9). Not all pancreatic cancer cells show high levels of migration in 
response to GDNF (10). Pancreatic cancer cells, which migrate in response to GDNF, also proliferate upon 
GDNF treatment. Cells responding robustly to GDNF were shown to be heterozygous for the rs1799939 
(p.G691S) RET allele and over-expression of rs1799939 increased invasion. The p.G691S polymorphism was 
present in 37% of primary cancers and in 31% of the matched normal pancreas. Levels of RET expression 
were the same in those with and without the polymorphism. The p.G691S polymorphism has been 
similarly implicated in the biology of desmoplasia melanoma, another neurotrophic disease (11). In 
addition RET is overexpressed in 50-65% of pancreatic cancers (10, 12, 13). 
Pre-clinical data in vitro, showed that the combination of vandetanib with gemcitabine provided synergistic 
cytotoxicity (14). Vandetanib increased the expression of deoxycytidine kinase (dCK) and the 
dCK/RRM1xRRM2 ratio. dCK is required to phosphorylate gemcitabine allowing its cytotoxic and cytostatic 
effects. Gemcitabine-sensitive pancreatic cancer cells may have higher levels of dCK than resistant cells 
and gemcitabine resistance is associated with down-regulation of dCK (15). In a highly metastatic 
orthotropic pancreatic cancer model, tumour weight was significantly less with the combination of 
gemcitabine and vandetanib than in those animals treated with either agent alone (16). The combination 
ViP/Lancet Oncology/Revised Tracked   3rd November 2016 
Page 6 of 35 
 
also significantly increased apoptosis in the primary tumour. Gemcitabine alone did not impact on the 
development of metastases but none of five combination-treated animals developed liver metastases, 
whilst all gemcitabine-treated mice developed nodal metastases compared with only one of five 
combination-treated animals. 
We report here the final results of a randomised phase II study comparing gemcitabine plus placebo with 
gemcitabine plus vandetanib in patients with advanced pancreatic cancer. We also report here the 
biomarker analysis of outcome according to p.G691S RET polymorphism status and additionally examine 
selected SNPs that have been proposed as being predictive of the activity of other angiogenesis inhibitors 




The vandetanib in pancreatic cancer (ViP) trial was a phase II placebo-controlled blinded randomised trial 
to compare gemcitabine plus vandetanib against gemcitabine plus placebo in patients with locally-
advanced or metastatic pancreatic ductal adenocarcinoma. Patients were recruited from 18 UK hospitals, 
which were centrally coordinated by the Cancer Research United Kingdom Liverpool Cancer Trials Unit 
(LCTU). The trial was reviewed and endorsed by the West London REC 2 Research Ethics Committee (MREC 
REF: 11/LO/0097). 
Participants 
Patients were eligible if they were at least 18 years old and diagnosed with locally advanced or metastatic 
carcinoma of the pancreas. Patients had to have an Eastern Cooperative Oncology Group (ECOG) score of 
zero, one or two and a documented life expectancy greater than 3 months. Patients undergoing curative or 
definitive locally directed therapies were excluded as were any patients who had undergone major surgery 
or radiotherapy within 4 weeks previous to randomisation.  Patients were further excluded if they had 
received previous chemotherapy for locally advanced or metastatic disease. Adjuvant chemotherapy for 
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resected pancreatic cancer was permitted provided that chemotherapy was completed > 12 months 
previously.   All patients entering the study gave their written informed consent following a full explanation 
of the study and after reading the patient information sheet. 
Randomisation and Masking 
Fisher Clinical Services (Fisher Clinical Services, Horsham, United Kingdom) were contracted to manage the 
drug (randomisation, dispensing, and discontinuation) and unblinding of patients.  Patients were 
randomised to each treatment group on a 1:1 basis according to computer generated permuted blocks of 
variable size.   Patients were stratified at randomisation by their disease stage (locally advanced versus 
metastatic) and their ECOG performance status (0/1 versus 2).  Prior to randomisation, staff at the LCTU 
verified patient details and eligibility criteria before being forwarded to Fisher to complete the 
randomisation process. Masking was achieved by using tablets with identical appearance in numbered 
bottles. Fisher allocated patients to each treatment group and directly informed the Pharmacy at each site, 
which numbered bottle to distribute to which patients. Only staff at Fisher were unblinded to treatment 
allocation prior to the end of the study. Patients were unmasked only in the event of a possible Suspected 
Unexpected Serious Adverse Reaction (SUSAR).  An independent clinical coordinator via direct 
communication carried out unblinding with Fisher. 
Procedures 
Gemcitabine was administered at 1000mg/m2 weekly as a 30-minute infusion for seven continuous weeks 
followed by a one week break.   Following this, gemcitabine was prescribed on a cycle of three continuous 
weeks followed by a one week break. Vandetanib was prescribed orally once a day at 300mg/day.  Placebo 
was prescribed to replicate the vandetanib prescription. Treatment continued until disease progression, 
intolerable toxicity despite supportive measures and dose modifications or withdrawal of consent.  
Patients were followed up continually until either death or end of study. 
Outcomes  
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The primary outcome measure was overall survival.   Secondary outcome measures were progression-free 
survival, objective response rate, disease control rate, toxicity and patient pain assessments.  Toxicity 
assessments were assessed following the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4·02 definitions.  Patient response to therapy was measured using the Response Evaluation Criteria 
in Solid Tumors (RECIST) version 1·1 (17) 
Best radiological response was defined as complete response, partial response, stable disease or 
progressive disease.  Objective response was defined as any patient with a complete or partial response.  
Disease control was defined as any patient with stable disease, a partial response or a complete response.  
Pain assessments were made using a 100 point visual analogue scale.  The trial was subject to 100% source 
data verification of all outcome data. 
Translational Methodology 
Carbohydrate Antigen (CA) 19·9 levels were measured at the participating site hospital clinical laboratories 
C-reactive protein (CRP) levels were measured at the Royal Liverpool Hospital Clinical Laboratories (upper 
limit of normal = 5 mg/l). All other analyses were undertaken centrally in the LCTU GCPLabs. 
Single nucleotide polymorphism (SNP) analyses for RET p.G691S, IL-8 rs4073, VEGF-A rs699947 and FLT1 
rs9582036 were undertaken using predesigned TaqMan® MGB probes (ThermoFisher Scientific, United 
Kingdom). Genomic DNA was extracted from patient blood using an automated MagNA Pure Compact 
Instrument (Roche Diagnostics, Germany) with the MagNA Pure Compact Nucleic Acid Isolation Kit I, 
according to the manufacturer’s instructions. Polymerase chain reactions (PCRs) were performed on a 
Roche Lightcycler 480. Patients were classified as heterozygous or homozygous for each allele. 
Immunohistochemistry for RET was undertaken on formalin-fixed paraffin-embedded (FFPE) tissue 
biopsies. Antigen retrieval and de-paraffinisation of sections was performed in pH9 Target Retrieval 
Solution (Dako, United Kingdom) using a PT link. Sections were incubated for 1 hour at room temperature 
with anti-RET antibody (clone EPR2871, ab134100, Abcam, United Kingdom) diluted 1:20 in Antibody 
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Diluent (Dako, United Kingdom). A further 1 hour incubation followed with Envision™ anti-rabbit HRP 
secondary antibody (Dako, United Kingdom) before visualisation with DAB chromogen. All slides were 
stained simultaneously to account for batch variation, alongside healthy kidney tissue sections for use as 
controls. 
Sections containing tumour cells were scored independently by two investigators, including a specialist 
histopathologist (FC). Both were blind to the patient data. Where there was disagreement a consensus was 
reached. Scores were given on a scale of 0-3 based on intensity of staining. In cases where heterogeneous 
staining was observed, the lowest score was given for that patient. 
Statistical Analysis  
Study design and sample size calculations were carried out with reference to similar trials performed in the 
same type of patient group (4, 18, 19).  From these, it was estimated that a survival rate of 51% at 6 
months would be observed for the control group.  It was estimated that with the addition of vandetanib an 
increase in 6 month survival rate to 67%, an absolute improvement of 16% corresponding to a hazard ratio 
of 0·6 would be considered sufficiently clinically relevant to warrant progression to phase III studies.  Using 
a one-sided α level of 0·1, a total of 100 deaths were required to obtain 90% Power resulting in a total 
sample size of 120 patients (60 in each treatment group).  The study design incorporated a single interim 
analysis to assess futility after 50 deaths had been observed.  The inclusion of this analysis reduced the 
overall type I error rate from 0·1 to 0·096 for assessment of the primary endpoint at the point of final 
analysis. During the course of the study, the decision to extend recruitment to recruit 140 patients was 
made to account for patient drop-out and ensure sufficient quantities of good quality translational 
materials were collected.  The impact was to extend the target number of deaths to 109 and to increase 
the trial power to 91·8%. 
Overall survival was measured as the time from randomisation until death by any cause.  Patients still alive 
at the point of final analysis were censored at the date last seen alive.  Progression free survival was 
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measured as the time from randomisation until disease progression.  Patients alive and without 
progression at the point of final analysis were censored at the date last seen alive.  Survival estimates were 
obtained using the Kaplan-Meier (20) method and compared across treatment groups using a stratified 
log-rank test (21).   The effect of treatment allocation is expressed as a hazard ratio (gemcitabine plus 
vandetanib versus gemcitabine plus placebo) with an associated 95% confidence interval.  Secondary 
analysis was carried out by adjusting the treatment effect using multivariable regression techniques based 
on Cox proportional hazards models (22).  Stratification factors and treatment effects are included in all 
models.  Univariate factors with a log rank significance of P<0·25 are considered for inclusion.  A forward 
step-wise regression approach is used with terms included based on Akaike Information Criteria (AIC) (23). 
The use of translational factors as possible indicator of treatment efficacy were assessed via Cox 
proportional hazards models including a treatment effect as an interaction term with each translational 
factor. 
Treatment administration was reported as the median (range) of cycles of each drug received.  The 
proportion of grade 3-4 toxicity was compared across treatments.   The number of patients observing high 
grade events across each AE was compared using a Χ2 test. 
All statistical analyses were carried out using the statistical package R (version 3.2). All analyses were 
carried out on an intention to treat principle, retaining patients in their randomised groups irrespective of 
any protocol violations.  A one-sided P-value of 0·096 (with 80·8% CI) was considered significant for the 
analysis of the primary endpoint and assessment of the treatment effect.  For all other analyses a nominal 
two sided P < 0·05 was used (with 95% CI). 
The trial was assessed at regular intervals by an Independent Data and Safety Monitoring Committee 
(IDSMC), which was responsible for assessing the trial in terms of safety and efficacy.  The IDSMC was un-
blinded to treatment allocation throughout the full course of the trial.  The trial was registered with the 
UKCRN (2007-004299-38). 
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Role of the Funding Source 
ViP was an investigator-initiated (non-commercial) trial, and no direct payments were available to cover 
the costs associated with patient recruitment, treatment administration, follow-up visits, data collection or 
travel expenses. The trial was part of the Cancer Research UK and AstraZeneca collaboration portfolio. As 
part of this collaboration there was unrestricted funding to support the trial from AstraZeneca to the 
Cancer Research UK Liverpool CTU, University of Liverpool (Chief Investigator for funding purposes: 
Professor John P Neoptolemos). The trial was endorsed by Cancer Research UK, consequently with 
endorsement from the National Cancer Research Network (NCRN, UK) and UK Clinical Research Network 
(UKCRN). The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation or writing of the report.  The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 




A total of 381 patients were screened for the trial of which 142 were randomised between the 24th 
October 2011 and 7th October 2013.   Two further patients were recruited beyond the recruitment target 
as they had already returned written informed consent at the point at which randomisation was complete.  
One patient was lost-to-follow up in the study and one patient withdrew consent. Follow-up data were 
included up to 15th July 2015 when the final database was locked for analysis with 131 deaths (target 109 
deaths) after a median follow up of 24·9 (24·3, NA) months. The CONSORT diagram is shown in Figure 1.   
Seventy patients were randomised to the gemcitabine plus placebo arm and 72 were randomised to the 
gemcitabine plus vandetanib arm.  The baseline characteristics of all randomised patients are shown in 
Table 1. Forty-one patients (29%) had locally advanced disease and 101 (71%) had metastatic disease.  The 
median age was 67 and 58% of patients were female; 11% of participants had an ECOG performance status 
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of 2. Baseline characteristics were mostly well balanced between arms, including baseline CA19·9 and CRP 
levels but there were significantly more patients in the vandetanib and gemcitabine arm with body 
tumours and more patients who were current and ex-smokers.  
One-hundred and thirty-one patients had died at the time of analysis, 61 (87%) in the placebo group and 
70 (97%) in the vandetanib group.  There was no difference in overall survival between the treatment 
groups (Figure 2a). The median (95% CI) overall survival was 8·95 (6·55-11·7) months and 8·83 (7·11-11·6) 
months for the gemcitabine-placebo and gemcitabine-vandetanib arms respectively (hazard ratio = 1·21, 
80.8% CI = 0·95, 1·53; log rank test (X21df) = 1·1 , P = 0·303).  Six and 12 month median (95% CI) survival 
estimates were 62% (52% - 75%) and 34% (25% - 48%) for the gemcitabine-placebo arm and 61% (51% - 
74%) and 36% (27% - 49%) for the gemcitabine-vandetanib arm respectively. There was no evidence of a 
differential effect for the addition of vandetanib to gemcitabine by stage of disease. In patients with locally 
advanced disease the median survival was 10·9 (0·16 - 20·5) months in the gemcitabine plus placebo arm 
and 12·1 (9·97 - 16·1) months in the gemcitabine plus vandetanib patients arm [HR: 1·13 (0·59 - 2·19), P-
value: 0·713]. In metastatic patients, the median survival was 7·20 (4·74 - 11·9) months in the gemcitabine 
plus placebo arm and 7·11 (4·21 - 11·2) in the gemcitabine plus vandetanib arm [HR: 1·13 (0·59 - 2·19); P = 
0·713] 
The results of univariable analysis of baseline characteristics as survival factors are shown in Table 2.   In 
multivariable analysis ECOG performance status, tumour histology and CA19·9 and CRP levels were 
independent prognostic factors (Table 3).  Following adjustment, the treatment effect changes little (HR = 
1·32; 95% CI = 0·91, 1·89, P=0·14). 
Table 4 shows the results of the prognostic and predictive power of the levels of CA19·9 and CRP, the SNPs 
in RET (p.G691S), VEGFR1 (rs9582036), VEGF (rs699947) and IL8 (rs4073) and the results of 
immunohistochemistry scoring superimposed on ECOG performance status and histology.   Continuous 
data were dichotomised at their observed median for illustration but all Cox models retain them as 
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continuous covariables.  Seventy-six (62·5%; Hardy-Weinberg = 63·8%) of 122 patients were germ line 
common homozygous (GG) for the RET p.G691S SNP, 43 (35·2%; Hardy-Weinberg = 32·2%) were 
heterozygous (GA) and three (2·5%; Hardy-Weinberg = 4·0%) were rare homozygous (AA). There was 
sufficient tissue from 66 (46·5%) patients for accurate RET expression immunohistochemistry scoring of 
which 40 (60·6%) had positive scores (examples are shown in Figure 5). Core biopsies were mostly 
homogeneous producing a single score but in eighteen cases there was a discrepancy in the scores. We 
present here the results using the lowest score to be representative which showed no association with 
survival in either treatment arm (Table 4). A sensitivity analysis showed that taking the highest score to be 
representative in the 18 cases with heterogeneous scores did not significantly affect the results of the first 
analysis. 
One-hundred and thirty-six patients had progressed or died at the time of analysis, 65 (93%) in the 
gemcitabine-placebo group and 71 (99%) in the gemcitabine-vandetanib group. The median (95% CI) 
progression-free survival estimates were 6·09 (5-9.9) months and 8·04 (·454-10·3) months for the 
gemcitabine-placebo and gemcitabine-vandetanib arms, respectively (Figure 2b; stratified log-rank test 
=1·11, 95% CI = 0·88-1·41, P = 0·554). 
Nineteen patients achieved an objective radiological response, nine (13%) on the gemcitabine-placebo arm 
and 10 (14%) in the gemcitabine-vandetanib arm (odds ratio = 1·06, 95% CI = 0·39-2·88, P =0·916) and the 
disease control rates were 75/142 (53%) and 82/142 58% respectively (odds ratio =1·419, 95% CI = 0·507 - 
3·972, P= 0·505). 
There were no treatment related deaths in either arm. Selected Grade 3-4 adverse events are presented in 
Table 5. Due to the small sample size and the low occurrence rates, P values were not that meaningful for 
many of the adverse events and so have been omitted. Neutropenia was more common in patients 
receiving vandetanib (p = 0·055), as was prolonged QT interval (p = 0·028) and rash (p=0·058). There was 
an increased incidence of grade 3 chronic kidney disease (a reduction of estimated glomerular filtration 
ViP/Lancet Oncology/Revised Tracked   3rd November 2016 
Page 14 of 35 
 
rate to 15 – 29 mls/min) in five (7%) of patients receiving gemcitabine and vandetanib compared to none 
in patients receiving gemcitabine plus placebo. Grade 2 chronic kidney disease (a reduction of estimated 
glomerular filtration rate to 30 – 50 mls/min) was seen in three (5%) patients in the gemcitabine plus 
placebo arm and 14 (20%) in the gemcitabine and vandetanib arm. There was no significant difference in 
grade 3-4 diarrhoea. Grade >2 rash was more prevalent in patients treated with vandetanib; 19% (14/72) 
on the gemcitabine plus vandetanib versus 6 % (4/70) on the gemcitabine plus placebo arm (P = 0·021).  
The median (IQR) time to the development of grade >2 rash was 131 (88, 195) days. Exploratory analysis 
showed that patients developing a rash on the combination of gemcitabine plus vandetanib had improved 
survival compared with those patients receiving gemcitabine plus vandetanib and not developing a rash 
and compared with those patients receiving gemcitabine alone. The median survival for the 14 patients 
receiving vandetanib and developing grade >2 rash was 11·92 (10·89 – NA) months, for the 58 patients 
receiving vandetanib and not developing grade >2 rash this was 7·76 (4·34 – 11·5) months and for the 
patients receiving gemcitabine plus placebo this was 8·95 (6·55 – 11·7) months (log rank Χ2 2df = 7·23; P= 
0·027). Median progression-free survival was also greater in patients receiving vandetanib and developing 
a rash >2 of 11·15 (10·2 – 21·12) months, compared to those without a grade >2 rash of 4·85 (3·78 – 8·98) 
months and 6·09 (5·0 – 9·9) months for those on gemcitabine plus placebo. With gemcitabine plus placebo 
as the reference group the hazard ratio for overall survival for the gemcitabine plus vandetanib without 
development of rash >2 was 1·41 (0·98 - 2·04; P = 0·065) and for gemcitabine plus vandetanib with the 
development of a rash >2, this was 0·655 (0·35 - 1·22; P = 0·181. The test for interaction for survival by 
treatment arm and rash was significant (P = 0·0162). Landmark analysis was carried out after excluding 
patients who died within 3 months and gave hazard ratios of 1.48 (0.974, 2.238) for gemcitabine plus 
vandetanib without development of rash >2  and 0.79 (0.419, 1.49) for gemcitabine plus vandetanib with 
the development of a rash >2. 
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The median (IQR) number of gemcitabine administrations was 12 (7, 21) in patients receiving gemcitabine 
and placebo and 13 (7, 22) in those receiving gemcitabine plus vandetanib. The percentage (95% CI) of 
gemcitabine delivered at full protocol dose was 70% (50·6 - 85·9) in patients receiving gemcitabine and 
placebo and 63·2% (51·9 -73·7) in those receiving gemcitabine plus vandetanib. 
DISCUSSION 
 
This trial showed that the addition of vandetanib to gemcitabine therapy did not improve the overall 
survival of patients with advanced pancreatic cancer when compared with gemcitabine alone. The 
combination of gemcitabine and vandetanib was generally well tolerated. Although grade 3-4 neutropenia 
was increased this did not translate to greater febrile neutropenia and the increased rash and QT 
prolongation in patients receiving vandetanib are already known side effects. This study included patients 
with both locally-advanced disease as well as metastatic patients as this was a signal-seeking randomised 
phase II study and patients were stratified at study entry for stage of disease and there was no mechanistic 
reason why there should be a differential response based on stage. 
In vitro studies suggest that the p.G691S RET polymorphism may distinguish pancreatic cancer cells that 
proliferate, migrate and invade neural tissue under the influence of GDNF, from those that do not (10). 
There was no evidence however in the current study, that patients who were germ line heterozygous for 
the p.G691S RET polymorphism obtained any incremental clinical benefit from the addition of vandetanib. 
Furthermore, there was no evidence that tissue expression of RET was a predictive biomarker for the 
addition of vandetanib. None of the VEGF pathway SNPs investigated in the current study showed any 
association with vandetanib outcomes. Previously it had been shown that the rs9582036 SNP was the only 
one of 138 VEGF pathway SNPs to be associated with survival in patients with pancreatic cancer receiving 
bevacizumab in combination with gemcitabine and erlotinib but not in the control arm (24). This SNP was 
in high linkage disequilibrium with a SNP that enhanced VEGFR1 mRNA translation and VEGFR1 expression. 
The VEGF SNP rs699947 was selected based on its association with survival in patients treated with 
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paclitaxel/bevacizumab and not in those with paclitaxel alone in the randomized E2100 trial in breast 
cancer (25). This SNP has also been associated with improved outcome in patients with pancreatic cancer 
treated with chemoradiation plus sorafenib (26). Finally, the IL8 polymorphism rs4073 was previously 
shown to be associated with overall survival in renal cancer patients treated with pazopanib and sunitinib 
(27) and also associated with response to ifosfamide and bevacizumab in ovarian cancer patients (28).  
Exploratory analysis showed that the development of a rash typical of that seen in patients treated with 
other EGFR inhibitor was predictive of both overall and progression free survival. Patients on vandetanib 
with gemcitabine who developed a rash had a doubling of survival compared with those not developing a 
rash on vandetanib and those patients receiving placebo with gemcitabine. This adds to the existing 
evidence for the development of rash as a surrogate biomarker of biological activity in patients receiving 
EGFR tyrosine kinase inhibitors in pancreatic cancer (4, 5).  
Vandetanib combines anti-RET activity together with VEGFR2 and EGFR inhibition. The benefit of EGFFR 
blockade and of additional VEGF inhibition in pancreatic cancer is modest but we hypothesised that the 
addition of RET inhibition to dual EGFR/VEGFR2 blockade would provide further therapeutic benefit. In 
spite of the pre-clinical data suggesting that RET could be a valid target in pancreatic cancer we found no 
evidence of a RET-based predictive biomarker. Furthermore inhibition of neural invasion may be less 
important once the primary has already locally invaded peri-neural tissue and/or the cancer has already 
metastasized. Whilst, the development of rash with agents targeting EGFR appears to be highly predictive 
of an improved outcome, attempts to dose to rash has so far not enhanced response in pancreatic cancer 
(29). Further research may be directed towards tyrosine kinase inhibitors in pancreatic cancer identifying 
biomarkers that could predict the development of a rash to vandetanib and also other tyrosine kinase 
inhibitors in pancreatic cancer. 
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PANEL: RESEARCH IN CONTEXT 
Evidence Before This Study 
We searched PubMed for all randomised trials in advanced pancreatic cancer. We also searched PubMed 
for any experimental work pertaining to RET in pancreatic cancer and for all clinical trials in which 
vandetanib, a RET, VEGFR2 and EGFR inhibitor, or any other RET inhibitors had been used in any cancer. 
Our review showed that the outcome of patients with pancreatic cancer remains extremely poor with 
median survivals even with the most aggressive regimens being under a year. For many patients 
gemcitabine monotherapy remains standard of care because of their inability to tolerate the more 
aggressive regimens. Thus, well-tolerated combinations with gemcitabine are urgently needed. RET is the 
receptor for the GDNF family of ligands. Neural invasion via a GDNF gradient is a prominent feature of 
pancreatic cancer causing pain and mediating the spread of the disease. Pancreatic cancer cells which carry 
the p.G691S polymorphism migrate more rapidly towards GDNF. Pre-clinical models have shown 
synergistic cytotoxicity for the gemcitabine/vandetanib combination in pancreatic cancer and reduced 
metastasis formation compared with gemcitabine alone in mouse models. A phase III trial of vandetanib in 
patients with advanced medullary thyroid cancer which over-expresses RET showed a survival benefit 
compared with placebo (30). Hence, we performed a randomised phase II trial of gemcitabine with or 
without vandetanib in advanced pancreatic cancer. 
Added value of this study 
Tissue acquisition for biomarker discovery was a crucial component of the trial and we were able to 
perform a comprehensive evaluation of the predictive and prognostic power of the p.G691S polymorphism 
along with a number of SNPs that have been associated with responses to agents targeting the VEGF 
pathway. We also analysed the predictive impact of RET immunostaining. 
Implication of all the available evidence 
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There was no evidence that the addition of vandetanib to gemcitabine improved outcome compared to 
gemcitabine alone in patients with advanced pancreatic cancer. There was also no evidence of any sub-
group effect with respect to RET or VEGF-related biomarkers. Further exploration of RET inhibition in 
advanced pancreatic cancer would not appear to be warranted. Whether further investigation of RET 
inhibition in earlier stage disease before significant invasion and migration occurs remains unknown. Since 
vandetanib is a multikinase inhibitor it is possible that as yet unidentified subgroups may benefit from its 
addition to gemcitabine. The development of rash typical of that seen in patients treated with other EGFR 
inhibitors were predictive of both overall and progression free survival in patients on vandetanib with 
gemcitabine. Further studies to investigate potential predictive biomarkers are required. 
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31. FIGURES AND TABLES 
 
Figure 1: Consort Diagram. 
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Figure 3: (a) Overall survival by CA19.9 levels and treatment arm. (b) Overall survival by CRP levels and 
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Figure 5: Examples of RET staining by immunohistochemistry in pancreas tissue biopsies. Scale bar = 50µm.
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Table 1: Baseline characteristics of the intention to treat population 
Clinical Characteristic 





Gender, number (%) 
 
      
Male 30 (43%) 29 (40%) 59 (42%) 0·888 
Female 40 (57%) 43 (60%) 83 (58%)   
Age, median (inter-quartile range) years 67·5 (61, 73) 66·5 (61, 73) 67 (61, 73) 0·558 
Disease Stage, number (%) 
 
      
Locally advanced 20 (29%) 21 (29%) 41 (29%)   
Metastatic 50 (71%) 51 (71%) 101 (71%) 1 
ECOG Performance Status, number (%) 
 
      
0 19 (27%) 21 (29%) 40 (28%) 0·965 
1 43 (61%) 43 (60%) 86 (61%)   
2 8 (11%) 8 (11%) 16 (11%)   
Tumour Histology, number (%) 
 
      
Pancreatic ductal adenocarcinoma 62 (89%) 66 (92%) 128 (90%)   
Undifferentiated carcinoma of the 
pancreas 
8 (11%) 6 (8%) 14 (10%) 0·736 
Tumour Site, number (%) 
 
      
Head  47 (67%) 31 (43%) 78 (55%)   
Uncinate  5 (7%) 4 (6%) 9 (6%) 0·017 
Body  13 (19%) 24 (33%) 37 (26%)   
Tail 5 (7%) 13 (18%) 18 (13%)   
Tumour Differentiation, number (%) 
 
      
Well 7 (10%) 6 (8%) 13 (9%) 0·6701 
Moderate 12 (17%) 16 (22%) 28 (20%)   
Poor 15 (21%) 16 (12%) 30 (22%)   
Unknown 29 (41%) 30 (42%) 59 (42%)   
Cannot be assessed 7 (10%) 4 (6%) 11 (8%)   
Smoking Status, number (%) 
 
      
Current Smoker 10 (15%) 19 (28%) 29 (21%) 0·026 
Ex-Smoker 23 (34%) 30 (43%) 53 (39%)   
Never Smoked 34 (51%) 20 (29%) 54 (40%)   
CA19-9*, median (inter-quartile range) 
mg/l 
1259·5 (264·75,6080·25) 1018 (199, 6104) 1100 (223, 6104) 0·659 
CRP*, median (inter-quartile range) mg/l 8 (0, 23) 10 (0, 46) 8.5 (0, 28·5) 0·175 
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Table 2: Univariable analysis 
of prognostic variables. * 
Hazard ratios obtained by 
modelling continuous data on 





Median overall survival 




   
  
Gemcitabine plus placebo 70 (61) 8·95 (6·55-11·7) 
 
  
Gemcitabine plus vandetanib 72 (70) 8·83 (7·11, 11·6) 1·17 (0·83, 1·65) 0·376 
Gender 
   
  
Female 59 (55) 8·.32 (5·.82, 11·4) 
 
  
Male 83 (76) 9·38 (6·68, 11·9) 0·94 (0·67, 1·34) 0·744 
Age 
   
  
<65 years 60 (53) 10·08 (4·87, 12·70) 
 
  
>65 years 82 (78) 8·75 (6·68, 11·0) 1·01 (0·99, 1·03) 0·546 
Disease Stage 
   
  
Locally advanced 41 (37) 11·53 (9·97, 15·16) 
 
  
Metastatic 101 (94) 7·11 (4·74, 9·97) 1·42 (0·97, 2·08) 0·071 
ECOG Performance Status 
   
  
0 40 (36) 11·58 (8·16, 15·2) 
 
  
1 86 (79) 8·91 (7·40, 11·3) 1·32 (0·88, 1·97)   
2 16 (16) 4·59 (3·91, 10·2) 2·46 (1·34, 4·51) 0·012 
Tumour Histology 
   
  
Pancreatic ductal adenocarcinoma 128 (117) 8·95 (7·70, 11·5) 
 
  
Undifferentiated carcinoma of the 
pancreas 
14 (14) 6·23 (3·39, 11·6) 2·06 (1·17, 3·64)  0·013 
Tumour Site 
   
  
Body 37 (36) 8·22 (5·82, 12·3) 
 
  
Head 78 (70) 9·97 (7·73, 11·6) 0·84 (0·56, 1·26)   
Tail 18 (16) 9·67 (3·59,NA) 0·81 (0·45, 1·46)   
Uncinate 9 (9) 5·00 (2·4, NA) 1·33 (0·64, 2·77) 0·52 
Tumour Differentiation 
   
  
Well 13 (11) 13·59 (12·43, NA) 
 
  
Moderate 28 (24) 10·69 (8·22, 19·14) 1·47 (0·70, 3·07)   
Poor 31 (29) 6·25 (4·38, 11·58) 2·47 (1·20, 5·08)   
Unknown 59 (57) 7·11 (4·54, 9·97) 2·490 (1·22, 4·72)   
Cannot be assessed 11 (10) 10·86 (8·03, NA) 1·37 (0·57, 3·31) 0·018 
Smoking Status 
   
  
Never 29 (27) 11.02 (7.83, 13.6) 
 
  
Past 53 (51) 9.61 (7.11, 13.4) 0.96 (0.60, 1.53)   
Present 54 (47) 8.32 (5.07, 11.2) 0.98 (0.61, 1.58) 0.983 
CA19-9, KU/I 
   
  
< 1100 69 (61) 12·1 (10·86, 15·16) 
 
  
> 1100 63 (60) 7·11 (4·84, 8·95) 1·14 (1·05, 1·24)* 0·001* 
CRP, mg/l 
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Table 2: Univariable analysis 
of prognostic variables. * 
Hazard ratios obtained by 
modelling continuous data on 





Median overall survival 
Hazard ratio (95% 
confidence interval) 
P 
< 8 62 (56) 11·48 (9·.97, 15·23) 
 
  




Table 3: Multivariable analysis by overall survival. *CRP and *CA19.9 included on the log transformed scale 
Factor HR (95% CI P-value 






Ambulatory (Work Able) 1·44 (0·94, 2·19) 0·091 
Ambulatory (Not Work Able) 2·29 (1·17, 4·48) 0·003 
Tumour Histology, number (%) 
 
  
Pancreatic ductal adenocarcinoma 
 
  
Undifferentiated carcinoma of the pancreas 1·88 (1·04, 3·41) 0·038 
CA19.9 levels* 1·15 (1·06, 1·24) 0.001 
CRP levels* 1·42 (1·21, 1·66) <0·001 
Arm, number (%) 
 
  
Gemcitabine plus placebo 
 
  
Gemcitabine plus vandetanib 1·32 (0·91, 1·89) 0·14 
   
Table 4: Overall survival by prognostic translational factors and the SNPs in RET (rs1799939 and p.G691S), VEGFR1 
(rs9582036), VEGF rs699947) and IL8 (rs4073).  *P-value denotes interaction effect.
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P Hazard ratio P* 
CA19-9 KU/I* 









<1100 69 (61) 12·11 (10·86, 15·16) 
 
  32 (25) 11·70 (7·50, 19·08) 
 
  37 (36) 12·43 (11·41, 15·16) 
 
  1·51 (0·87, 2·60)   








0·005 32 (31) 4·85 (4·11, 8·22) 
1·10 (0·98, 
1·23) 
0·105 1·70 (0·99, 2·93) 0·318 
CRP                             
< 8 62 (56) 11·48 (9·97, 15·23) 
 
  32 (27) 10·20 (8·95, 18·29) 
 
  30 (29) 12·35 (11·02, 16·05) 
 
  1·21 (0·68, 2·15)   








0·028 33 (33) 4·11 (3·12, 7·99) 
1·51 (1·23, 
1·86) 
<0·001 1·09 (0·59, 1·99) 0·635 
RET p·G691S 
   
  
   
  




Major Allele 76 (70) 9·10 (7·11, 11·00) 
 
  36 (32) 9·31 (4·87, 13·00) 
 
  40 (38) 8·83 (4·84, 12·40) 
 
  1·20 (0·73, 1·97)   
Heterozygous 
(G/A) 








0·635 23 (23) 10·89 (7·40, 16·20) 
1·18 (0·66, 
2·10) 
0·583 1·30 (0·66, 2·59) 0·933 
IL-8 rs4073                             
AA 28 (25) 8·37 (4·21, 15·60) 
 
  10 (8) 5·13 (2·80, NA) 
 
  18 (17) 9·36 (4·44, 16·1) 
 
  0·97 (0·40, 2·39)   








0·613 50 (49) 10·54 (7·40, 12·40) 
1·30 (0·70, 
2·42) 
0·411 1·50 (0·97, 2·33) 0·389 
VEGFA 
rs699947    
  
   
  




AA 32 (31) 8·85 (7·50, 12·10) 
 
  11 (10) 8·95 (6·35, NA) 
 
  21 (21) 8·75 (5·79, 12·70) 
 
  0·95 (0·43, 2·13)   








0·194 47 (45) 10·20 (7·11, 13·00) 
0·76 (0·43, 
1·33) 
0·331 1·31 (0·83, 2·04) 0·44 
VEGF (FLT1) 
rs9582036 
                            
AA 69 (66) 8·32 (6·68, 11·00) 
 
  30 (27) 8·55 (6·35, 13·00) 
 
  39 (39) 8·32 (4·87, 12·10) 
 
  1·64 (0·94, 2·84)   








0·187 29 (27) 11·41 (8·22, 14·30) 
0·67 (0·39, 
1·15) 
0·147 0·88 (0·50, 1·55) 0·093 
Imunohisto-
chemistry Score 
                            
0 26 (25) 7·30 (4·74, 12·30)    10 (9) 6·28 (4·74, NA)    16 (16) 7·40 (4·11, 14·3)     0·87 (0·33, 2·29)   
1 28 (26) 5·77 (4·21, 10·20) 
1·47 
(0·79, 
0·224 14 (13) 8·34 (4·38, 19·1) 
1.33 
(0·49, 
0·573 14 (13) 4·44 (4·01, 15·2) 
1·51 (0·60, 
3·82) 
0·385 1·32 (0·52, 3·37)  
ViP/Lancet Oncology/Revised Tracked   3rd November 2016 
Page 33 of 35 
 
2·75)  3·62) 
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Table 5: Summary of Adverse Events   
 
Toxicity 





GGT increased 32 (46%) 29 (40%) 
Neutrophil count decreased 22 (31%) 35 (49%) 
Platelet count decreased 16 (23%) 20 (28%) 
Fatigue 15 (21%) 17 (24%) 
White blood cell decreased 13 (19%) 12 (17%) 
Hypertension 11 (16%) 9 (12%) 
ALT increased 11 (16%) 8 (11%) 
Hyponatremia 8 (11%) 10 (14%) 
ALP increased 10 (14%) 8 (11%) 
Lethargy 7 (10%) 9 (12%) 
Lymphocyte count decreased 6 (9%) 9 (12%) 
Diarrhea 4 (6%) 7 (10%) 
Blood bilirubin increased 3 (4%) 4 (6%) 
Abdominal Pain 5 (7%) 2 (3%) 
Anorexia 4 (6%) 3 (4%) 
Prolonged QT interval 0 (0%) 6 (8%) 
AST 2 (3%) 4 (6%) 
Anaemia 3 (4%) 3 (4%) 
Dyspnoea 2 (3%) 3 (4%) 
Chronic kidney disease 0 (0%) 5 (7%) 
Rash maculo-papular 0 (0%) 5 (7%) 
Investigations - Other 1 (1%) 4 (6%) 
Nausea 2 (3%) 3 (4%) 
Ascites 1 (1%) 3 (4%) 
Vomiting 3 (4%) 1 (1%) 
Hyperglycemia 1 (1%) 2 (3%) 
Abdominal pain 0 (0%) 3 (4%) 
Hypokalemia 2 (3%) 1 (1%) 
Hypomagnesemia 1 (1%) 2 (3%) 
Hypoalbuminemia 2 (3%) 1 (1%) 
Hypoxia 1 (1%) 1 (1%) 
Syncope 1 (1%) 1 (1%) 
Renal and urinary disorders 1 (1%) 1 (1%) 
Hypotension 0 (0%) 2 (3%) 
Thromboembolic event 1 (1%) 1 (1%) 
Pain 0 (0%) 2 (3%) 
Dizziness 0 (0%) 2 (3%) 
Leukocytosis 0 (0%) 2 (3%) 
Oedema limbs 1 (1%) 1 (1%) 
Papulopustular rash 0 (0%) 2 (3%) 
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Toxicity 





Creatinine increased 1 (1%) 1 (1%) 
Hyperthyroidism 1 (1%) 0 (0%) 
Blurred vision 1 (1%) 0 (0%) 
Vertigo 1 (1%) 0 (0%) 
Colitis 1 (1%) 0 (0%) 
Obstruction gastric 1 (1%) 0 (0%) 
Bile duct stenosis 1 (1%) 0 (0%) 
Surgical and medical procedures  1 (1%) 0 (0%) 
Left ventricular systolic dysfunction 0 (0%) 1 (1%) 
Encephalopathy 0 (0%) 1 (1%) 
Pulmonary edema 0 (0%) 1 (1%) 
Purpura 0 (0%) 1 (1%) 
Respiratory, thoracic and medical diseases  0 (0%) 1 (1%) 
Dyspepsia 0 (0%) 1 (1%) 
Pleural effusion 0 (0%) 1 (1%) 
Bronchial infection 1 (1%) 0 (0%) 
Pain in extremity 1 (1%) 0 (0%) 
Skin ulceration 0 (0%) 1 (1%) 
Gastrointestinal disorders Ð Other 0 (0%) 1 (1%) 
Biliary tract infection 0 (0%) 1 (1%) 
Depression 1 (1%) 0 (0%) 
Infections and infestations - Other 0 (0%) 1 (1%) 
Cough 1 (1%) 0 (0%) 
Fever 0 (0%) 1 (1%) 
Skin - other 0 (0%) 1 (1%) 
Back pain 0 (0%) 1 (1%) 
Constipation 0 (0%) 1 (1%) 
Hyperkalemia 0 (0%) 0 (0%) 
Mucositis oral 0 (0%) 0 (0%) 
Hypocalcemia 0 (0%) 0 (0%) 
 
 
 
